Medications to treat alcohol dependence: Adding to the continuum of care

JAMA

Volumn 298, Issue 14, 2007, Pages 1691-1692

  Willenbring, Mark L ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; AMINO ACID RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; DRUG DERIVATIVE; FRUCTOSE; TOPIRAMATE;

ADVERTIZING; ALCOHOLISM; BEHAVIOR THERAPY; CAUSE OF DEATH; CLINICAL EDUCATION; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERABILITY; EDITORIAL; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; MENTAL HEALTH CARE; OUTPATIENT CARE; PATIENT COUNSELING; PHYSICIAN; PRIORITY JOURNAL; NOTE; PATIENT CARE;

ALCOHOLISM; BEHAVIOR THERAPY; CONTINUITY OF PATIENT CARE; EXCITATORY AMINO ACID ANTAGONISTS; FRUCTOSE; GABA MODULATORS; HUMANS;

EID: 35348896606     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.14.1691     Document Type: Editorial

References (14)

1. McLellan AT, Carise D, Kleber HD. Can the national addiction treatment infrastructure support the public's demand for quality care? J Subst Abuse Treat. 2003;25(2):117-121.
2. Mark TL, Kranzler HR, Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003;71(3):219-228.
3. Johnson BA, Rosenthal N, Capece JA, et al; for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.
4. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685.
5. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
6. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625.
7. Gueorguieva R, Wu R, Pittman B, et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry. 2007;61(11):1290-1295.
8. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(7):830-842.
9. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807-816.
10. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction. 2005;100(3):281-292.
11. Moss HB, Chen CM, Yi HY. Subtypes of alcohol dependence in a nationally representative sample. Drug Alcohol Depend. In press.
12. Willenbring ML, Olson DH. A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch Intern Med. 1999;159(16):1946-1952.
13. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-1245.
14. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician's guide. http://www.niaaa.nih.gov/guide. Accessibility verified September 17, 2007.